BioSpace News Archive

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in ACCESS CHINA Biotech Forum.

Sema4 today announced the appointment of Gustavo Stolovitzky , PhD, to the newly established senior leadership position of Chief Science Officer (CSO).

Acepodia today announced that it will present new interim data from an ongoing Phase 1 study ( NCT04319757 ) evaluating ACE1702 at the European Society of Medical Oncology (ESMO) 2021 Annual Congress being held virtually September 16-21, 2021.

New data from various studies of Eli Lilly and Company’s (NYSE: LLY) Verzenio ® (abemaciclib), Retevmo ® (selpercatinib) and CYRAMZA ® (ramucirumab) will be presented at the European Society for Medical Oncology (ESMO) Congress 2021, to be held virtually September 16-21

OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has published a study identifying a predictive proteomic signature for patient response to immune checkpoint inhibitor (ICI) therapy in non-small-cell lung carcinoma (NSCLC) patients.

Thermo Fisher Scientific Inc., the world leader in serving science, announced the launch of the Thermo Scientific AutoFLEX EFM, which is the company’s newest addition to the AutoSERIES Flow Computer product portfolio utilized in the oil and gas industry for flow measurement and process control.

Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that Brazil’s National Health Surveillance Agency (ANVISA) has approved FERRIPROX® (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.

Oncology Pharma, Inc. the Company has obtained, received and segregated all funds necessary to execute the first phase of the development project of a nanoemulsion of dactinomycin, with the initial tranche released as scheduled.

Amylyx Adds Data from CENTAUR to the Anonymized PRO-ACT Database, the Largest ALS Clinical Trial Dataset Ever Created

Cellworks Group, Inc. today announced that results from patient stratification studies will be featured in four poster presentations at the IASLC 2021 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer and held virtually September 8-14, 2021.